The Chemours Company

Report azionario NYSE:CC

Capitalizzazione di mercato: US$3.6b

Chemours Gestione

Criteri Gestione verificati 2/4

Chemours Il CEO è Denise M. Dignam, nominato in Feb2024, e ha un mandato di 2.25 anni. la retribuzione annua totale è $ 8.60M, composta da 12.3% di stipendio e 87.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.053% delle azioni della società, per un valore di $ 1.89M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.3 anni e 2.2 anni.

Informazioni chiave

Denise M. Dignam

Amministratore delegato

US$8.6m

Compenso totale

Percentuale dello stipendio del CEO12.32%
Mandato del CEO2.3yrs
Proprietà del CEO0.05%
Durata media del management2.3yrs
Durata media del Consiglio di amministrazione2.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Articolo di analisi May 08

The Chemours Company Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

It's been a mediocre week for The Chemours Company ( NYSE:CC ) shareholders, with the stock dropping 17% to US$22.41 in...
Seeking Alpha May 04

Chemours: Thesis Materialization In 2026 (Rating Downgrade)

Summary Chemours Company has delivered a 120%+ RoR in under six months, driven by strong refrigerant segment growth, especially Opteon adoption. Despite recent outperformance, CC now trades above my fair value target ($30/share), prompting a shift to a 'HOLD/Neutral' rating and portfolio rotation. CC remains fundamentally sound but faces persistent risks: high leverage ($3.5B net debt), regulatory liabilities, and cyclical end-market exposure, especially in TiO2. Future upside hinges on continued refrigerant growth, cost reductions, and deleveraging; current valuation reflects excessive optimism relative to near-term fundamentals. Read the full article on Seeking Alpha
Aggiornamento dell'analisi Apr 22

CC: Cooling Partnership And 2026 Outlook Will Support Further Earnings Upside

Analysts now cite slightly higher long term revenue growth, profit margin, and P/E assumptions as reasons for raising Chemours fair value estimate from $25.00 to $29.00 per share. What's in the News Chemours and 2CRSi entered a Joint Development Agreement following the qualification of Chemours' Opteon two phase immersion cooling fluid in current generation 2CRSi servers, aimed at advancing two phase cooling technologies for high density IT infrastructure and AI workloads (Key Developments).
Aggiornamento dell'analisi Apr 08

CC: Share Repurchases And 2026 Outlook Will Support Earnings Upside

Analysts have raised their Chemours price target from $21.00 to $25.00, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Chemours completed its share repurchase program announced on May 2, 2022, buying back 10,342,722 shares (6.76%) for a total of $309.28 million, with no additional shares repurchased between October 1, 2025 and December 31, 2025 (Key Developments).
Aggiornamento dell'analisi Mar 24

CC: PFAS Litigation Will Drive Cautious Outlook Despite Cooling Technology Partnership

Analysts have maintained their $17.00 price target for Chemours, citing updated assumptions that include a 10.25% discount rate, 3.37% revenue growth, a 13.84% profit margin, and a future P/E of 3.87x, which they state continue to support the prior fair value view. What's in the News Chemours reported that between October 1, 2025 and December 31, 2025, it repurchased 0 shares for US$0 under its existing program and indicated that it has completed the buyback of 10,342,722 shares, or 6.76%, for US$309.28 million under the authorization announced on May 2, 2022 (Key Developments).
Aggiornamento dell'analisi Mar 09

CC: PFAS Legal Overhang And Cooling Partnership Will Shape Balanced Return Outlook

Analysts have raised their price target on Chemours from $13.00 to $17.00, citing updated assumptions around discount rate, revenue growth, profit margins, and future P/E that change their view of the company’s risk and earnings potential. What's in the News Chemours and 2CRSi entered a Joint Development Agreement after Chemours' Opteon two phase immersion cooling fluid was qualified in current generation 2CRSi servers, with a focus on advanced cooling for high density IT, AI, and next generation chips, and an emphasis on end user and environmental benefits.
Aggiornamento dell'analisi Feb 22

CC: Earnings Outlook And PFAS Legal Overhang Will Shape Future Upside

Analysts have revised their Chemours price target from $18.00 to $21.00, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that slightly adjust the risk and earnings profile they are using in their models. What's in the News Chemours issued new Full Year 2026 earnings guidance, with management indicating an expectation for Net Sales growth in the 3% to 5% range.
Aggiornamento dell'analisi Feb 08

CC: PFAS Class Action Risk Will Limit Future Shareholder Returns

Analysts have kept their Chemours fair value estimate steady at $13.00, with the latest price target grounded in unchanged fair value assumptions, along with updated views on discount rate, revenue growth, profit margin and future P/E levels. What's in the News On January 6, 2026, a Montana federal judge denied motions to dismiss a class action against DuPont/Chemours, 3M and several other gear and materials manufacturers related to alleged toxic PFAS chemicals in firefighter turnout gear.
Articolo di analisi Feb 03

The Chemours Company (NYSE:CC) Shares Fly 27% But Investors Aren't Buying For Growth

The The Chemours Company ( NYSE:CC ) share price has done very well over the last month, posting an excellent gain of...
Aggiornamento dell'analisi Jan 25

CC: Legal Overhang And Margin Reset Will Shape Balanced Outlook

Analysts have trimmed their price target on Chemours to about US$16 from roughly US$18, pointing to adjustments in profit margin expectations and valuation multiples, even though assumptions for revenue growth and future P/E have shifted. What's in the News A Montana federal judge denied motions to dismiss a class-action lawsuit involving PFAS in firefighter turnout gear, allowing claims against DuPont/Chemours and other manufacturers to move forward, including Racketeer Influenced Corrupt Organizations (RICO) claims that will remain active pending a related Ninth Circuit decision (Lawsuits & Legal Issues).
Aggiornamento dell'analisi Jan 11

CC: PFAS Lawsuit And Weaker Margins Will Restrain Future Shareholder Returns

Analysts have kept their Chemours fair value estimate steady at US$13.00. The latest price target update reflects adjusted assumptions around discount rate, revenue growth, profit margin and future P/E rather than a change in headline valuation.
Aggiornamento dell'analisi Dec 26

CC: Future Profitability Challenges Will Temper Benefits Of Completed Share Buybacks

Analysts have modestly raised their price target on Chemours to 13.00 dollars, reflecting slightly stronger revenue growth expectations and higher assumed future valuation multiples, while this is partially offset by a more cautious view on long term profitability and risk. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).
Aggiornamento dell'analisi Dec 12

CC: Long-Term Margin Outlook Will Offset Near-Term Losses And Completed Buybacks

Analysts have raised their price target on Chemours from 11 dollars and 41 cents to 13 dollars, reflecting expectations for significantly stronger long term profit margins, despite slightly more conservative assumptions for revenue growth and valuation multiples. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).
Aggiornamento dell'analisi Nov 01

CC: Global Supply Agreements And Buybacks Will Drive Undervalued Shares Higher

Analysts have adjusted their price target for Chemours. They are maintaining the fair value estimate at $17.78, but have slightly increased the discount rate and are projecting a modest decrease in both expected revenue growth and profit margin based on recent outlook factors.
Aggiornamento dell'analisi Oct 17

Low GWP Refrigerants And Advanced Materials Will Drive Future Success

Analysts have raised their price target for Chemours by $1.00, reflecting updated assumptions for modestly improved fair value and profit margin forecasts. What's in the News Chemours has entered into strategic agreements with SRF Limited to strengthen its global supply chain, enhance operational flexibility, and increase capacity for key materials such as fluoropolymers and fluoroelastomers (Key Developments).
Aggiornamento dell'analisi Oct 03

Low GWP Refrigerants And Advanced Materials Will Drive Future Success

Analysts have raised their price target for Chemours from $15.44 to $16.78, citing improved profit margins and slight increases in projected revenue growth as key factors for the update. What's in the News Chemours signed strategic agreements with SRF Limited to strengthen its global supply chain, increase operational flexibility, and secure fluoropolymer and fluoroelastomer capacity for multiple industries (Client Announcements).
Aggiornamento dell'analisi Sep 17

Low GWP Refrigerants And Advanced Materials Will Drive Future Success

The modest increase in Chemours’ Consensus Analyst Price Target reflects slightly higher forward P/E expectations, while the discount rate remains stable, resulting in a revised fair value of $15.44. What's in the News Chemours signed strategic agreements with SRF Limited to enhance global supply chain, increase operational flexibility, and access capacity for fluoropolymers and fluoroelastomers, with no upfront capital investment required.
Articolo di analisi Sep 03

The Chemours Company (NYSE:CC) Held Back By Insufficient Growth Even After Shares Climb 33%

The Chemours Company ( NYSE:CC ) shares have continued their recent momentum with a 33% gain in the last month alone...
Articolo di analisi Jul 26

Is It Time To Consider Buying The Chemours Company (NYSE:CC)?

The Chemours Company ( NYSE:CC ), is not the largest company out there, but it saw a significant share price rise of...
Articolo di analisi Jul 04

The Chemours Company's (NYSE:CC) Price Is Right But Growth Is Lacking After Shares Rocket 30%

The Chemours Company ( NYSE:CC ) shares have had a really impressive month, gaining 30% after a shaky period...
Articolo di analisi Jun 29

Chemours (NYSE:CC) Has No Shortage Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Articolo di analisi May 14

We Like The Quality Of Chemours' (NYSE:CC) Earnings

Despite posting healthy earnings, The Chemours Company's ( NYSE:CC ) stock has been quite weak. Along with the solid...
Articolo di analisi Apr 25

Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?

Key Insights The projected fair value for Chemours is US$23.71 based on 2 Stage Free Cash Flow to Equity Chemours is...
Articolo di analisi Mar 19

What Is The Chemours Company's (NYSE:CC) Share Price Doing?

The Chemours Company ( NYSE:CC ), might not be a large cap stock, but it saw significant share price movement during...
Articolo di analisi Mar 04

It's Down 27% But The Chemours Company (NYSE:CC) Could Be Riskier Than It Looks

To the annoyance of some shareholders, The Chemours Company ( NYSE:CC ) shares are down a considerable 27% in the last...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Denise M. Dignam rispetto agli utili di Chemours?
DataCompenso totaleStipendioUtili della società
Mar 31 2026n/an/a

-US$410m

Dec 31 2025US$9mUS$1m

-US$386m

Sep 30 2025n/an/a

-US$338m

Jun 30 2025n/an/a

-US$430m

Mar 31 2025n/an/a

US$10m

Dec 31 2024US$6mUS$904k

US$69m

Sep 30 2024n/an/a

US$63m

Jun 30 2024n/an/a

US$106m

Mar 31 2024n/an/a

-US$329m

Dec 31 2023US$2mUS$532k

-US$253m

Sep 30 2023n/an/a

-US$317m

Jun 30 2023n/an/a

-US$87m

Mar 31 2023n/an/a

US$489m

Dec 31 2022US$2mUS$463k

US$578m

Compensazione vs Mercato: La retribuzione totale di Denise M. ($USD 8.60M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 7.13M ).

Compensazione vs guadagni: La retribuzione di Denise M. è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Denise M. Dignam (59 yo)

2.3yrs
Mandato
US$8,595,077
Compensazione

Ms. Denise M. Dignam serves as Independent Director at Kulicke and Soffa Industries, Inc. from August 22, 2023. She serves as Chief Executive Officer amd Director at The Chemours Company since March 25, 20...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Denise M. Dignam
President2.3yrsUS$8.60m0.053%
$ 1.9m
Shane Hostetter
Senior VP & CFO1.8yrsUS$2.75m0.011%
$ 399.4k
Kristine Wellman
Senior VP3.6yrsUS$1.96m0.022%
$ 788.1k
Gerardo Calderon
President of Advanced Performance Materials3.2yrsUS$1.53m0.012%
$ 411.8k
Joseph Martinko
President of Thermal & Specialized Solutions2.8yrsUS$1.67m0.0081%
$ 289.2k
David Will
Controller & Chief Accounting Officer1.8yrsNessun dato0.0039%
$ 137.2k
Brandon Ontjes
Vice President of Investor Relations2.9yrsNessun datoNessun dato
Matthew Conti
Chief Human Resources Officerless than a yearNessun datoNessun dato
Aditya Beri
Interim President of Titanium Technologies & Chemical Solutions Business3.2yrsNessun datoNessun dato
Diane Picho
Chief Enterprise Enablement Officer2.2yrsNessun dato0.018%
$ 654.5k
Michael Foley
President of Titanium Technologiesless than a yearNessun dato0.0023%
$ 82.8k
2.3yrs
Durata media
54yo
Età media

Gestione esperta: Il team dirigenziale di CC è considerato esperto (durata media dell'incarico 2.3 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Denise M. Dignam
President2.2yrsUS$8.60m0.053%
$ 1.9m
Mary Cranston
Independent Chair10.8yrsUS$315.00k0.015%
$ 535.8k
Livingston Satterthwaite
Independent Director1.9yrsUS$288.12k0%
$ 0
Alister Cowan
Lead Independent Director2.5yrsUS$298.12k0.0068%
$ 241.3k
Sean Keohane
Independent Director8yrsUS$292.50k0.0039%
$ 138.6k
George Brokaw
Independent Director1.1yrsUS$248.75k0%
$ 0
Joseph Kava
Independent Director1.3yrsUS$275.00k0%
$ 0
Leslie Turner
Independent Director1.3yrsUS$275.00k0%
$ 0
Courtney Mather
Independent Director1.1yrsUS$248.75k0%
$ 0
Erin Kane
Independent Director6.9yrsUS$292.50k0%
$ 0
Pamela Fletcher
Independent Director2.2yrsUS$275.00k0%
$ 0
2.2yrs
Durata media
58yo
Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di CC non è considerato esperto (durata media del mandato 2.2 anni), il che suggerisce un nuovo consiglio.


Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/07 00:04
Prezzo dell'azione a fine giornata2026/05/07 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

The Chemours Company è coperta da 19 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
null nullAlembic Global Advisors
David ColemanArgus Research Company
Michael LeitheadBarclays